HC Wainwright Lowers Earnings Estimates for Shattuck Labs

Shattuck Labs, Inc. (NASDAQ:STTK) – Research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of Shattuck Labs in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.54) for the year, down from their previous estimate of ($1.41). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

Several other research analysts have also recently weighed in on STTK. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Citigroup lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday. Four analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Trading Down 9.9 %

NASDAQ STTK opened at $1.24 on Monday. Shattuck Labs has a 1-year low of $1.07 and a 1-year high of $11.76. The stock has a 50-day moving average of $2.08 and a 200-day moving average of $4.19. The firm has a market cap of $58.95 million, a PE ratio of -0.81 and a beta of 1.85.

Insider Transactions at Shattuck Labs

In related news, CEO Taylor Schreiber bought 36,500 shares of the stock in a transaction dated Monday, October 7th. The shares were purchased at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the completion of the purchase, the chief executive officer now directly owns 71,002 shares of the company’s stock, valued at $85,912.42. This represents a 105.79 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On Shattuck Labs

Large investors have recently made changes to their positions in the company. Atom Investors LP acquired a new position in shares of Shattuck Labs in the third quarter worth about $35,000. Readystate Asset Management LP purchased a new position in shares of Shattuck Labs in the 3rd quarter valued at about $39,000. Benjamin Edwards Inc. acquired a new position in Shattuck Labs in the 3rd quarter worth about $61,000. The Manufacturers Life Insurance Company purchased a new position in Shattuck Labs during the second quarter worth approximately $67,000. Finally, MetLife Investment Management LLC grew its holdings in Shattuck Labs by 129.1% in the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock valued at $86,000 after purchasing an additional 13,859 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.